← Back to All Filings

Sanofi Finalizes Acquisition of Dynavax in a $1.31B Tender Offer

High SignificanceFebruary 10, 2026 at 11:09:50 AM UTC

DYNAVAX TECHNOLOGIES CORP

SC TO-T/ACIK: 0001029142

Filing Summary

Sanofi Finalizes Acquisition of Dynavax in a $1.31B Tender Offer

Company: Dynavax Technologies Corp Form: SC TO-T/A | Filed: 2026-02-10 Significance: High

Acquirer: Sanofi Relationship: Offeror

Transaction: • Type: Tender Offer Purchase • Shares Tendered: 84,680,752 • Price: $15.50 • Value: $1,312,551,656 • Ownership After: ~73.92% (leading to full merger)

Key Insight: Sanofi has successfully completed its tender offer, acquiring a controlling stake in Dynavax. This action will trigger a full merger and the delisting of Dynavax shares from the NASDAQ.

Market Context: This filing confirms the final results of the tender offer, marking the end of Dynavax as a publicly traded entity and its integration into Sanofi.

Comprehensive Analysis

SEC Filing Analysis: Dynavax Technologies Corp

Executive Summary

  • Trading Significance: High
  • Key Takeaway: Sanofi has successfully acquired a controlling stake of approximately 73.92% in Dynavax Technologies Corp through a tender offer valued at over $1.31 billion, paving the way for a full merger and delisting of Dynavax stock.
  • Market Impact: This is a definitive change-of-control event, concluding Dynavax's tenure as an independent public company.

Company Information

FieldValue
CompanyDynavax Technologies Corp
Ticker SymbolDVAX (Note: Not in filing, but publicly known; will be delisted)
CIK0001029142
IndustryPharmaceutical Preparations

Acquirer Information

FieldValue
NameSanofi
CIK0001121404
Title/PositionNot Applicable
RelationshipOfferor / Acquirer

Transaction Details

FieldValue
Form TypeSC TO-T/A
Transaction Date2026-02-09
Transaction CodeNot Applicable (Tender Offer)
Security TypeCommon Stock, Par Value $0.001 Per Share
Shares Involved84,680,752
Price Per Share$15.50
Total Value$1,312,551,656
Shares Owned AfterNot specified, but total holding represents ~73.92% of outstanding shares
Ownership TypeIndirect (via Samba Merger Sub, Inc.)

Financial Impact Assessment

Transaction Materiality

Note: The provided market data was for the acquirer (Sanofi). The following analysis is based on data derived from the filing for the target company (Dynavax) for accurate context.

MetricValue
Transaction Value$1,312,551,656
Estimated Target Market Cap~$1.78 Billion (based on offer price and implied shares outstanding)
% of Market Cap~73.9%
Shares Transacted84,680,752
% of Shares Outstanding~73.9% (of total shares outstanding, based on filing data)
Post-Transaction Ownership~73.92% of outstanding shares
Materiality AssessmentHighly Significant

Impact Evaluation

  • Market Cap Context: The transaction value represents a complete buyout of Dynavax, a multi-billion dollar entity. This is not an insider trade but a full corporate acquisition.
  • Ownership Concentration: Sanofi, through its subsidiary, has moved from a potential suitor to the controlling majority shareholder, enabling it to execute a short-form merger without a stockholder vote.
  • Dilution Impact: Not applicable. This is an acquisition of existing shares, not an issuance of new ones. The event is terminal for public shareholders, who will be cashed out.
  • Transaction Significance: As a change-of-control transaction representing the vast majority of the company's equity and market value, the significance is maximal.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: This filing confirms the results of the tender offer. For remaining Dynavax shareholders, their shares will be converted to cash at the $15.50 offer price upon the merger's completion. Trading will cease, and the stock will be delisted, ending its public market journey.

Volume & Sentiment

  • Expected Volume Impact: Trading volume will cease upon delisting.
  • Sentiment Indicator: Neutral. The event is a finalized acquisition, not a speculative market event. The outcome is now certain for shareholders.

Investment Insights

Positive Market Indicators

  • The successful tender offer indicates strong shareholder acceptance of the $15.50 per share valuation.
  • For Sanofi, this represents a strategic acquisition to bolster its portfolio.

Risk Factors

  • All risks are now moot for Dynavax public shareholders, as the company is being acquired and they will be cashed out.

Key Takeaways

  1. Acquisition Complete: Sanofi's tender offer for Dynavax was successful, with 84,680,752 shares tendered.
  2. Change of Control: Sanofi now controls ~73.92% of Dynavax, sufficient to proceed with a merger and take the company private.
  3. Delisting Imminent: Dynavax shares will be delisted from the NASDAQ Global Select Market, and shareholders not part of the tender will receive cash for their shares.

Additional Context

Transaction Notes

  • This filing is Amendment No. 3 to the original Schedule TO, serving as the final amendment reporting the results of the tender offer.
  • The offer expired at one minute following 11:59 P.M., Eastern Time, on February 9, 2026.
Topics:SECFilingAcquisitionMergerTenderOfferSanofiDynavaxSCTOTBiotechPharmaStockMarket

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is AI-generated from public SEC filings and may contain errors. It is for informational and educational purposes only and is not investment, legal, or tax advice.

The Filing Fool is not a registered investment adviser, broker-dealer, or financial planner. Nothing here is a recommendation or solicitation to buy, sell, or hold any security.

Always do your own due diligence and consult a licensed professional.